At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 305 enrolled
Drug / intervention
clobetasol propionate spray 0.05% +1 moredrug
Likely dose
calcitriol ointment 3 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Open-Label Study to Evaluate the Safety and Efficacy of a Consecutive Treatment Regimen of Clobetasol Propionate 0.05% Spray, Followed by Calcitriol Ointment 3µg/g, in the Management of Moderate to Severe Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating clobetasol propionate spray 0.05% and calcitriol ointment for Psoriasis. Completed, enrolled 305 participants across 12 sites.
Detailed Summary
The primary objectives of this study are to evaluate the safety \& efficacy of consecutive treatments of Clobex® Spray and Silkis® Ointment in the management of plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedApr 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedApr 15, 2008
Enrollment StartMar 1, 2008
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 18.2 years ago
Interventions
clobetasol propionate spray 0.05%drug
clobetasol propionate spray, 0.05%, applied topically twice daily
calcitriol ointmentdrug
calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily